drugset / Trial / NCT06066333
Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether pembrolizumab given after standard ablative Radiotherapy is a safe treatment that causes few or mild side effects in people with advanced Adrenocortical Carcinoma.
Timeline
- Start
- 2023-09-27
- Primary completion
- 2026-09-27
- Completion
- 2026-09-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | — | — |